share_log

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Chardan Capital维持seres therapeutics的买入评级,维持1.25美元的目标股价
Benzinga ·  11/14 07:56  · 评级/大行评级

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.

Chardan Capital分析师Keay Nakae维持Seres Therapeutics(纳斯达克股票代码:MCRB)的买入并维持1.25美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发